Presbia Announces the Appointment of Two Board Members
Presbia Holdings, a medical device company and leader in near vision restoration, announced today that it has appointed two new members to serve on its Board of Directors.
“We are very pleased to be adding Dr. Mark S. Blumenkranz and Randy Thurman to our Board,” said Zohar Loshitzer, Chief Executive Officer of Presbia. “They strengthen an already stellar group of Directors and Officers who possess extensive knowledge and expertise in ophthalmology and medical devices and who will be instrumental in our efforts to assist patients in improving their near vision.”
Dr. Blumenkranz is the H.J. Smead Professor and Chairman of the Department of Ophthalmology at Stanford University and is a noted ophthalmic surgeon. Dr. Blumenkranz focuses primarily on medical and surgical treatment of a variety of vitreoretinal diseases. He is an author of more than 100 peer-reviewed publications and book chapters in the area of vitreoretinal surgery, with special interests in surgical adjuvant pharmacology and new microsurgical and laser techniques. In addition to being an associate examiner for the American Board of Ophthalmology, Dr. Blumenkranz is also a member of the Retina, Vitreous, Macula and Gonin Societies and is the recipient of various awards in his field of expertise.
Mr. Thurman is the Executive Chairman of the Board for Cogent HMG, one of the nation's largest private hospitalist and intensivist companies. Mr. Thurman is also an Operating Executive with AEA Investors LP. He has held many senior positions with other major private and public equity firms and has over 25 years of healthcare industry experience. He was the founder, Chairman and CEO of VIASYS Healthcare, Inc. (NYSE: VAS). Additionally, Mr. Thurman has an extensive background in corporate governance and has served in various capacities on public company boards.
Detailed biographies of Dr. Blumenkranz and Mr. Thurman can be found on our website at www.presbia.com.
ABOUT PRESBIA AND THE PRESBIA FLEXIVUE MICROLENS™
Presbia Holdings is a leading ophthalmic-device company focused on the development of solutions for presbyopia, the age-related loss of the ability to read or focus on near objects. Chief among these approaches is the Presbia Flexivue Microlens™, a 3mm-diameter lens that is implanted in the corneal stroma of the patient's non-dominant eye using femtosecond laser technology. The procedure requires no general anesthesia and typical recovery periods are only a few days. The Presbia Flexivue Microlens™ solution utilizes standard equipment and ophthalmic surgical techniques, and requires only minimal additional staff training.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.